| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 59.39 mm | 59.39 mm | 59.39 mm | 59.39 mm | 59.39 mm | 59.39 mm |
| Cash burn (monthly) | 27.09 mm | 1.05 mm | 7.95 mm | 8.68 mm | 7.00 mm | 8.62 mm |
| Cash used (since last report) | 119.11 mm | 4.63 mm | 34.96 mm | 38.16 mm | 30.79 mm | 37.90 mm |
| Cash remaining | -59.73 mm | 54.76 mm | 24.43 mm | 21.23 mm | 28.60 mm | 21.49 mm |
| Runway (months of cash) | -2.2 | 52.0 | 3.1 | 2.4 | 4.1 | 2.5 |
| 13F holders | Current |
|---|---|
| Total holders | 83 |
| Opened positions | 15 |
| Closed positions | 7 |
| Increased positions | 28 |
| Reduced positions | 19 |
| 13F shares | Current |
|---|---|
| Total value | 368.68 bn |
| Total shares | 63.63 mm |
| Total puts | 2.40 k |
| Total calls | 8.60 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Flagship Pioneering | 12.67 mm | $118.00 bn |
| Flagship Ventures Fund V | 9.33 mm | $58.04 mm |
| FMR | 6.33 mm | $58.97 bn |
| Biotechnology Value Fund L P | 5.55 mm | $33.31 mm |
| BVF | 5.30 mm | $49.36 bn |
| LLY Eli Lilly and | 4.00 mm | $47.96 mm |
| Deerfield Management | 3.03 mm | $28.19 bn |
| Flynn James E | 2.94 mm | $29.32 mm |
| Raymond James & Associates | 2.30 mm | $21.39 bn |
| Klarman Family Foundation | 2.14 mm | $16.28 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Jan 25 | Michael LaCascia | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 126,000 | 550.62 k | 126,000 |
| 22 Jan 25 | Steven F. Bellon | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 140,000 | 611.80 k | 140,000 |
| 22 Jan 25 | Anna Rivkin | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 50,000 | 218.50 k | 50,000 |
| 22 Jan 25 | Adrian Gottschalk | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 400,000 | 1.75 mm | 400,000 |
| 22 Jan 25 | Carlos Costa | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 115,000 | 502.55 k | 115,000 |
